Assembly Biosciences Stock Cycle Indicators Hilbert Transform Dominant Cycle Period
| ASMB Stock | USD 28.12 -0.18 -0.64% |
| Symbol |
Indicator |
The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The Hilbert Transform - Dominant Cycle Period indicator is used to generate in-phase and quadrature components of Assembly Biosciences price series in order to analyze variations of the instantaneous cycles.
Assembly Biosciences Technical Analysis Modules
Most technical analysis of Assembly Biosciences help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Assembly from various momentum indicators to cycle indicators. When you analyze Assembly charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people. Market structure and macro sensitivity help explain how Assembly Biosciences behaves across regimes. Market sensitivity remains generally comparable to wider market conditions. Assembly Biosciences has a market cap of 444.7 M, ROE of -36.94%.
Methodology
Unless otherwise specified, financial data for Assembly Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Assembly (USA Stocks:ASMB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Assembly Biosciences is covered by 4 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, RBC Capital Markets, Wells Fargo Securities, BMO Capital Markets, Stifel, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardLearn to be your own money manager
Tracking Assembly Biosciences inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Assembly Biosciences pair trading
Pair trading with Assembly Biosciences can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Assembly Biosciences Pair Trading
Assembly Biosciences Pair Trading Analysis
Correlation matrices help investors optimize their Assembly Biosciences tax-loss harvesting strategy by identifying the best available substitutes. The higher the correlation to Assembly Biosciences, the less the portfolio's risk profile will shift during the wash-sale waiting period.
The pairwise correlation of Assembly Biosciences measures the historical tendency for two assets to move in the same or opposite directions. High correlations between Assembly Biosciences and another holding indicate concentrated risk that may amplify losses in adverse market conditions.
Use Correlation analysis and pair trading evaluation for Assembly Biosciences to review hedging context. The method can be applied across sectors and broader equity sets.More Resources for Assembly Stock Analysis
A comprehensive view of Assembly Biosciences starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for Assembly Biosciences Stock. Selected reports below provide context for Assembly Stock:Assembly Biosciences has a market cap of 444.7 M, operating margin of -100.87%, ROE of -36.94%. Review Trending Equities for broader portfolio context. This reflects a position in Assembly Biosciences within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Before investing in Assembly Stock, review our How to Buy Assembly Biosciences guide for key considerations.Analysis related to Assembly Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Earnings Share -4.60 | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Understanding Assembly Biosciences includes distinguishing between market value and book value, where book value reflects Assembly's accounting equity. Assembly Biosciences' market capitalization is 444.7 M. A P/B ratio of 2.44 indicates the market values Assembly Biosciences above its accounting book value. Enterprise value stands at 216.72 M. Intrinsic value reflects what Assembly Biosciences' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Assembly Biosciences' value from its trading price, which are computed with different methods. For Assembly Biosciences, key inputs include a P/B ratio of 2.44, a profit margin of -103.65%, ROE of -36.94%, and revenue of 28.52 M. The quoted price is simply the exchange level where supply meets demand.